Empire Genomics has obtained an exclusive license from Emory University covering a genomic biomarker that will be used to develop a molecular diagnostic test to help identify treatments best suited for multiple myeloma patients. Empire Genomics said a Phase II trial is being undertaken to test the capability of the technology in predicting response to newer drugs for the blood disease.